MedTech Dive March 18, 2024
Nick Paul Taylor

The NEJM paper presents data from a study of more than 10,000 people Guardant ran to support authorization of its Shield DNA test.

Dive Brief:

  • Guardant Health shared clinical data on its colorectal cancer screening blood test in The New England Journal of Medicine, as the company and rivals race to get blood tests to market for colon cancer detection.
  • The paper, which the NEJM published Thursday, presents data from a study of more than 10,000 people that Guardant ran to support authorization of its Shield DNA blood test.
  • Investors sent shares in Guardant down 27% when they first saw data from the study in 2022, but the company viewed the results positively. The Food and Drug Administration is...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Medical Devices, Patient / Consumer, Provider, Survey / Study, Trends
Related Articles:
Medicare Coverage Of Medical Technologies In A New Era
This year's top congressional medical technology priorities
Boston Scientific to acquire devicemaker: 3 things to know
Everything You Need To Know Before Getting An RFID Implant - 3
State Licensing Spotlight - Prescription medical device manufacturers & distributors: Regulatory considerations applicable to medical devices versus drugs

Share This Article